基于Nurr1/NFκB/TNF-α通路研究人参皂苷Rg1抗帕金森病的作用机制
批准号:
82104418
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
邵千航
依托单位:
学科分类:
中药神经精神药理
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
邵千航
中文摘要
人参皂苷Rg1是人参的活性化合物,被证实有神经保护作用,但其抗PD的作用机制尚未阐明。Nurr1分子是孤儿核受体超家族的转录因子,最近研究表明Nurr1在LPS诱导的小胶质细胞模型中可阻断NF-kB/p65与炎症基因启动子结合发挥抗炎作用,调节Nurr1活性可能成为治疗PD的新策略。由此提出“Rg1可调控Nurr1/NFκB/TNF-α通路抑制神经炎症反应从而发挥抗PD作用”这一科学假说。本课题拟以原代、传代小胶质细胞及A53T小鼠为研究对象,从动物行为学、细胞生物学及分子生物学等方面研究Rg1对小胶质细胞数量形态,Nurr1分子核转位和表达以及对Nurr1/NFκB/TNF-α通路的影响;通过慢病毒敲减Nurr1的表达,观察Rg1抗PD的作用是否受到干扰;最后对Rg1影响Nurr1活性过程中可能参与的上游分子机制进行探究,进而阐明Rg1的抗PD作用机制,为研发新型抗PD药物提供实验依据。
英文摘要
The Ginsenoside Rg1, an active component of ginseng, has been proved to have neuroprotective effects, but the underlying mechanisms have not been clarified. Nurr1 is a member of orphan nuclear receptors and has been studied extensively in PD recently. Nurr1 has been shown to inhibit the expression of proinflammatory mediators by docking to NF-κB-p65 on target inflammatory gene promoters in microglia. Nurr1 may be an important molecular target in the treatment of PD. Therefore, we propose a scientific hypothesis that "Ginsenoside Rg1 plays neuroprotective effects by regulating the Nurr1/NFκB/TNF-α pathway ". The primary microglia, BV-2 microglia cells and A53T transgenic mice were studied in this experiment. The purpose of this study is to show the effects of Rg1 on the number and morphology of microglia, the nuclear translocation and expression of Nurr1, and the Nurr1/NFκB/TNF-α pathway by the ethology, cell biology and molecular biology. When the expression of Nurr1 is knocked down by lentivirus, whether the neuroprotective effects of Rg1 are disturbed. Finally, the upstream molecular mechanisms that Rg1 may influence the activity of Nurr1 are explored. In conclusion, the present study will clarify the underlying mechanisms of Rg1, providing experimental basis for the development of new drugs.
人参皂苷Rg1是人参的主要活性成分,其毒性低、副作用少,且具有神经保护作用,但其抗PD的作用机制尚未阐明。Nurr1分子是孤儿核受体超家族的转录因子,是具有抗神经炎症和神经保护作用的重要转录因子,调节Nurr1活性可能成为治疗PD的新策略。血液-脑屏障的完整性对于正常的脑功能、突触重塑和血管生成至关重要。血脑屏障的破坏是帕金森病期间的常见病理改变,会导致脑内运输功能受损、通透性增加和神经毒性分子暴露增加,是神经炎症的主要诱发因素。本研究证实:(1)在细胞和动物水平上系统评估Rg1抗PD的药理效应,证实其通过改善黑质-纹状体多巴胺能神经元退行性病变缓解PD运动症状,同时改善神经炎症,减少血脑屏障损伤。(2)深入解析Rg1抗PD的分子机制,揭示其通过上调Nurr1表达实现神经保护效应的核心通路。整合Swiss Target Prediction靶点预测(基于配体结构的反向药效团匹配技术)、分子对接实验、免疫荧光共定位及Western blotting多组学技术,表明Rg1通过靶向VEGFA进而调控Nurr1的表达,从而影响血脑屏障的完整性和减轻神经炎症延缓帕金森病进展。本研究不仅为PD潜在治疗靶点的探索提供了重要的理论依据和实验线索,同时也为传统中药人参皂苷Rg1的现代化开发及其在神经退行性疾病中的创新应用开辟了新的思路。
国内基金
海外基金